Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 3,056 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Colon Clear all
Completed Not applicable Interventional

Increasing Colorectal Cancer Screening Among Filipino Americans

NCT00742729
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Arm 1, Arm 2, Arm 3
Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 70 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 31, 2026, 8:52 AM EDT
Active, not recruiting Not applicable Interventional

Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer

NCT03141437
View directory record Official record
Conditions
Breast Neoplasm, Colorectal Neoplasm, Female Reproductive System Neoplasm, Health Care Provider, Lymphoma, Plasma Cell Myeloma
Interventions
Best Practice, Educational Intervention, Internet-Based Intervention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

NCT01652196
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography)
Biological · Drug · Other + 2 more
Lead sponsor
John Hays
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 31, 2026, 8:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reducing Rural Colon Cancer Disparities

NCT03457454
View directory record Official record
Conditions
Colon Cancer
Interventions
Primary Care Provider/Staff Participants Interview, Patient Participant Interview, Patient Participant Anonymous Survey, Colonoscopy Provider/Staff Participants Interviews
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Carbondale, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Phase 1 Interventional

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

NCT00055705
View directory record Official record
Conditions
Cancer
Interventions
PV701
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT01975831
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 31, 2026, 8:52 AM EDT
Recruiting Phase 2 Interventional

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

NCT04779554
View directory record Official record
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2
Drug
Lead sponsor
Prakash Pandalai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Lexington, Kentucky • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 8:52 AM EDT
Recruiting Phase 1 Interventional

Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer

NCT06833866
View directory record Official record
Conditions
Advanced or Metastatic CRC
Interventions
Hydroxytyrosol
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment

NCT00942266
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
fluorouracil, leucovorin calcium, vorinostat, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population

NCT01385579
View directory record Official record
Conditions
Malignant Neoplasm of Large Intestine
Interventions
Care manager outreach
Other
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Phase 2 Interventional

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

NCT00091182
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer
Interventions
oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 31, 2026, 8:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial

NCT05291988
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Educational Intervention, Fecal Immunochemical Test, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Seattle, Washington • Sequim, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 31, 2026, 8:52 AM EDT
Not listed No phase listed Observational

Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors

NCT01311856
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Standard Arm (mail/telephone), Internet Arm, Surveys and Questionnaires, Exercise and Diet
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Not applicable Interventional

Default Genetics Referrals for Young-Onset Colorectal Cancer

NCT05018156
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Default Genetics Referral Process
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

NCT02368886
View directory record Official record
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Clobetasol Propionate, Pharmacological Study, Quality-of-Life Assessment, Regorafenib
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Not applicable Interventional

Use of Novel Tailored Reminders in Rural Primary Care

NCT00593073
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Electronic tailored messaging, General Reminder Message
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
50 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2008 · Synced Oct 31, 2026, 8:52 AM EDT
Recruiting Phase 1 Interventional

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

NCT07812805
View directory record Official record
Conditions
Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC), Gastric Cancer (GC), Esophageal Cancer (EC), Head and Neck Squamous Cell Cancer (HNSCC)
Interventions
SKL35501, SKL35502
Drug · Diagnostic Test
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Glen Burnie, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00002842
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, leucovorin calcium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Phase 2 Interventional

Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors

NCT00962494
View directory record Official record
Conditions
Blood Cancer, Breast Cancer, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms
Interventions
Cancer: Thriving and Surviving Online Workshop
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 31, 2026, 8:52 AM EDT
Terminated Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma

NCT00625183
View directory record Official record
Conditions
Colorectal Cancer
Interventions
selenomethionine, capecitabine, oxaliplatin, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
Dietary Supplement · Drug · Other + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 31, 2026, 8:52 AM EDT
Terminated Phase 1 Interventional

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

NCT04975256
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Interventions
MRTX849, BI 1701963
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
St Louis, Missouri • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 31, 2026, 8:52 AM EDT
Completed Not applicable Interventional

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

NCT01726296
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Squamous Cell Lung Cancer, Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions
educational intervention, medical chart review
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 31, 2026, 8:52 AM EDT
Terminated Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

NCT00091286
View directory record Official record
Conditions
Colorectal Cancer
Interventions
HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 31, 2026, 8:52 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Longitudinal Performance of Epi proColon

NCT03218423
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms
Interventions
Epi proColon
Device
Lead sponsor
Epigenomics, Inc
Industry
Eligibility
50 Years to 74 Years
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
6
States / cities
San Diego, California • Royal Oak, Michigan • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 31, 2026, 8:52 AM EDT